Katja[a]
Nippon Kayaku Obtains Additional Approval for Its Three Anti-tumor Agents
Tokyo (JCNN) - Nippon Kayaku has announced that it has received approval for additional indications of its three anti-tumor agents: Randa Inj., Lastet Inj., and Oncovin.
With this approval, as concomitant treatments with other agents, Randa can be used for malignant bone tumor and endometrial cancer, Lastet for pediatric malignant solid tumor, and Oncovin for multiple myeloma, malignant astrocytoma, and glioma with oligodendroglioma.
By Aki Tsukioka, JCNN
Feb 23, 2005